$GTBP

EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results - GT Biopharma (NASDAQ:GTBP)

GT Biopharma completed dosing in Cohort 1 and began Cohort 2 of its Phase 1 trial for GTB-3650 with no safety concerns. Early data shows increased NK cell activity, indicating promising immune response from its TriKE cancer therapy.

Original reporting
Benzinga · Mohit Manghnani
Published May 19, 2025, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 19, 2025, 1:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results - GT Biopharma (NASDAQ:GTBP) — source image
Decision brief

The 30-second read

$GTBPBullishMed
01

Why it matters

Positive early safety and immune response data may enhance investor confidence, potentially leading to increased stock valuation.

02

Market read

The trial's progress is relevant for biotech investors and could influence related sector stocks.

03

What to watch

Potential delays in trial progression, regulatory hurdles, or adverse safety findings could negate current optimism.

Timing: High, as upcoming trial results could influence stock price in the near term.

Background

GT Biopharma is advancing a novel TriKE cancer therapy targeting relapsed blood cancers, with recent safety data supporting progression to subsequent trial phases.

Company-level read

Ticker impact

$GTBPBullishMedium confidence
Context

The news pertains directly to GT Biopharma's clinical trial developments, which could influence its stock performance.

Expected impact

Moderate upward movement in the short to medium term, contingent on continued trial success and broader market conditions.

Evidence & confidence

While early safety and immune response data are encouraging, clinical trial outcomes are inherently uncertain, and the stock's reaction depends on subsequent data releases and market sentiment.

Market effects

The development could positively impact the biotech sector focusing on immunotherapies and cancer treatments.

Primarily affects US biotech stocks; limited immediate regional impact.

Moderate, as successful trial outcomes could influence global biotech investment sentiment.

Counterpoint

Skeptics may argue that early safety signals do not guarantee efficacy, and negative future data could lead to significant declines.

Key entities

  • GT Biopharma

    Biotech firm developing immuno-oncology therapies.

  • GTB-3650

    TriKE-based therapy for relapsed blood cancers.

Related articles

$GTBPLow

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout - GT Biopharm

GT Biopharma, a clinical-stage immuno-oncology company using its TriKE natural killer cell engager platform, said AI tools rolled out internally have improved discovery and drug engineering productivity. The company plans to advance lead programs GTB-3650 and GTB-5550 through Phase 1 studies this year and use AI for candidate selection, molecular design, and structural modeling. Shares were up 0.38% to $0.48 premarket, per Benzinga Pro.

$UWMCMed

UWM sued for allegedly misleading investors on hedge strategy

Shareholder Doug Bond filed a class action against UWM Holdings in Michigan federal court, alleging securities fraud over disclosures about UWM’s interest rate derivatives hedge tied to its Two Harbors acquisition. The suit covers purchases from March 9 to Aug. 5, citing a $603.2 million derivatives loss and a $2.05 billion Oaktree cash infusion after a March revenue projection.

$BAMedAI 8/10

Pentagon inks deals with Boeing, RTX to boost production of SM-3 components

The Pentagon signed seven-year framework agreements with Boeing and RTX to expand production of Standard Missile-3 components for SM-3 Block IB and Block IIA, including avionics and ejector assemblies Boeing supplies to Raytheon. The deals aim to stabilize supply chains and expand munitions output. Separately, the Missile Defense Agency awarded Raytheon a $745 million contract for Block IIA interceptors.

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

$MARAMed

Crypto Biz: Bitcoin ETFs Rebound as Crypto Miners Extend AI Pivot

A $116 million Coldcard hardware wallet exploit renewed scrutiny of self-custody as US spot Bitcoin ETFs saw about $1 billion in net inflows for the week, according to Bloomberg. Strategy CEO Phong Le said Strategy will resume Bitcoin accumulation later this year; Riot Platforms reported a 20-year $9 billion compute deal with Anthropic. Trump Media plans to revamp its crypto treasury after a $238 million Q2 net loss.